Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
E For L Aim PCLBKK:EFORL 36 5-Year Yield-on-Cost % is 0.00 as of Aug. 02, 2026. GuruFocus rates BKK:EFORL with a GF Score™ of 36/100 and a GF Value™ of ฿0.15 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 69 Medical Distribution companies, E For L Aim PCL ranks worse than 1449273.91% on this metric.
E For L Aim PCL's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for E For L Aim PCL's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, E For L Aim PCL's highest Yield on Cost was 16.92. The lowest was 0.00. And the median was 7.52.
BKK:EFORL's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.23 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
E For L Aim PCL (BKK:EFORL) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
E For L Aim PCL 5-Year Yield-on-Cost % Related Terms
BKK:EFORL vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, E For L Aim PCL's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
E For L Aim PCL 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, E For L Aim PCL's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where E For L Aim PCL's 5-Year Yield-on-Cost % falls into.
E For L Aim PCL 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of E For L Aim PCL is calculated as
E For L Aim PCL (BKK:EFORL) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on E For L Aim PCL and its competitors. According to the industry distribution chart, E For L Aim PCL ranks #999999 out of 69 companies in the Medical Distribution industry.
Is E For L Aim PCL's 5-Year Yield-on-Cost % too high?
E For L Aim PCL's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, E For L Aim PCL ranks #999999 out of 69 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, E For L Aim PCL has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does E For L Aim PCL's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, E For L Aim PCL ranks #999999 out of 69 companies for 5-Year Yield-on-Cost %. This places E For L Aim PCL in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.23, based on 69 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on E For L Aim PCL and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. E For L Aim PCL's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is E For L Aim PCL stock overvalued right now?
Based on GuruFocus' analysis, E For L Aim PCL (BKK:EFORL) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿0.15, compared to a current price of ฿0.12 — trading 20% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. E For L Aim PCL's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For E For L Aim PCL (BKK:EFORL), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is E For L Aim PCL (BKK:EFORL) Overvalued in 2026?
Based on GuruFocus' analysis, E For L Aim PCL stock appears to be undervalued.
The current stock price of ฿0.12 is trading 20% below its estimated GF Value™ of ฿0.15.
GuruFocus considers E For L Aim PCL to be Modestly Undervalued.
Key valuation signals for BKK:EFORL:
5-Year Yield-on-Cost %: 0.00
GF Value™: ฿0.15 vs. price of ฿0.12 (20% below fair value)
No single metric tells the full story. See the BKK:EFORL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
E For L Aim PCL is engaged in the distribution of medical devices and equipment. The company and subsidiary have distributor agreements for medical devices and equipment with foreign companies. Its products include Patient Monitor System, Central Monitors System, Defibrillator, Automated External Defibrillator (AED), Electrocardiographs, Electroencephalogram (EEG), PSG System (Sleep Labs), and Accessories and Consumables. The group is principally engaged in one operating segment which is the distribution of medical device and equipment and providing service of medical equipment. Their operations are carried out in Thailand.
36GF Score
Get the complete analysis for BKK:EFORL
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:EFORL has been successfully added to your 
